Windtree Therapeutics Future Growth

Future criteria checks 0/6

Windtree Therapeutics's earnings are forecast to decline at 17.3% per annum. EPS is expected to grow by 46.1% per annum.

Key information

-17.3%

Earnings growth rate

46.1%

EPS growth rate

Biotechs earnings growth	24.5%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	03 Jan 2024

Recent future growth updates

Recent updates

Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)

Dec 06

Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions

Jul 06

Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable

Jun 09

Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?

Feb 09

Earnings and Revenue Growth Forecasts

NasdaqCM:WINT - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-35	-30	-30	1
12/31/2025	N/A	-30	-27	-27	1
12/31/2024	N/A	-22	-19	-19	1
12/31/2023	N/A	-20	-13	-13	N/A
9/30/2023	N/A	-25	-13	-13	N/A
6/30/2023	N/A	-24	-13	-13	N/A
3/31/2023	N/A	-35	-15	-15	N/A
12/31/2022	N/A	-39	-19	-19	N/A
9/30/2022	N/A	-43	-21	-21	N/A
6/30/2022	N/A	-47	-22	-22	N/A
3/31/2022	N/A	-67	-25	-24	N/A
12/31/2021	N/A	-68	-24	-24	N/A
9/30/2021	N/A	-62	-24	-23	N/A
6/30/2021	N/A	-63	-27	-26	N/A
3/31/2021	N/A	-35	-26	-26	N/A
12/31/2020	N/A	-33	-26	-25	N/A
9/30/2020	N/A	-32	-26	-26	N/A
6/30/2020	N/A	-31	-22	-22	N/A
3/31/2020	0	-27	-22	-21	N/A
12/31/2019	0	-27	-25	-25	N/A
9/30/2019	1	-43	-26	-25	N/A
6/30/2019	1	-40	-25	-25	N/A
3/31/2019	2	-37	-22	-22	N/A
12/31/2018	2	-35	-16	-16	N/A
9/30/2018	2	-9	-14	-14	N/A
6/30/2018	1	-13	-14	-14	N/A
3/31/2018	1	-17	-16	-16	N/A
12/31/2017	1	-25	-21	-21	N/A
9/30/2017	2	-34	N/A	-23	N/A
6/30/2017	3	-35	N/A	-28	N/A
3/31/2017	2	-38	N/A	-32	N/A
12/31/2016	2	-39	N/A	-34	N/A
9/30/2016	2	-43	N/A	-34	N/A
6/30/2016	1	-56	N/A	-33	N/A
3/31/2016	1	-57	N/A	-34	N/A
12/31/2015	1	-55	N/A	-34	N/A
9/30/2015	2	-56	N/A	-36	N/A
6/30/2015	2	-45	N/A	-39	N/A
3/31/2015	3	-45	N/A	-40	N/A
12/31/2014	3	-44	N/A	-41	N/A
9/30/2014	2	-45	N/A	-41	N/A
6/30/2014	1	-46	N/A	-40	N/A
3/31/2014	0	-44	N/A	-40	N/A
12/31/2013	0	-45	N/A	-40	N/A
9/30/2013	1	-40	N/A	-39	N/A
6/30/2013	0	-41	N/A	-39	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: WINT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: WINT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: WINT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if WINT's revenue is forecast to grow faster than the US market.

High Growth Revenue: WINT is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if WINT's Return on Equity is forecast to be high in 3 years time

Windtree Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to US$3.00

Price target decreased to US$5.50

Price target decreased to US$8.25

Recent updates

Windtree Therapeutics Regains Compliance with Nasdaq

Windtree Therapeutics Approves 1-for-18 Reverse Stock Split and Expects Compliance with Listing Requirements of the $1.00 Minimum Bid Price Requirement by The Nasdaq Capital Market

Windtree Therapeutics, Inc. (NasdaqCM:WINT) acquired All of the assets of Varian Biopharmaceuticals, Inc.

Windtree Therapeutics, Inc. announced delayed annual 10-K filing

Windtree Therapeutics Receives Non-Compliance Notice from Nasdaq

New major risk - Revenue and earnings growth

Windtree Therapeutics, Inc. Announces the Start of Patient Dosing in Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.054024 million.

New major risk - Share price stability

Windtree Therapeutics, Inc. Appoints Jamie McAndrew as Controller, Chief Accounting Officer and Principal Accounting Officer

Windtree Therapeutics, Inc. Is Developing A Multi-Asset Franchise of Its Novel Serca2a Activators

Windtree Therapeutics, Inc. Appoints Mark Strobeck to its Board of Directors

Windtree Therapeutics, Inc. Announces Chief Financial Official Officer Changes

Nasdaq Grants Windtree Therapeutics 180-Day Extension to Regain Compliance

Price target decreased to US$3.00

Windtree Therapeutics, Inc. Announces Impairment Charges for the Three Months Ended September 30, 2022

Windtree Therapeutics, Inc. Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (Seismic) Published in the European Journal of Heart Failure

Windtree Therapeutics, Inc. Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America

Windtree Therapeutics, Inc. Reports Impairment for the Second Quarter Ended June 30, 2022

Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value

Windtree Therapeutics Receives Non-Compliance Letter from Nasdaq

Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid

Windtree Therapeutics, Inc. Announces Not Stand for Re-Election of Evan Loh from Board

Windtree Therapeutics, Inc., Annual General Meeting, Jun 07, 2022

Price target decreased to US$5.50

Windtree Therapeutics, Inc. Announces Positive Topline Results from Its Phase 2 Seismic Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics Completes Enrollment in its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress Syndrome

Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)

Windtree Therapeutics, Inc. Announces Results of U.S. Hospital Claims Data Analysis Showing Hospital Inpatient Mortality and Length of Hospital Stay for Cardiogenic Shock Patients

Independent Chairman of the Board recently bought US$95k worth of stock

Price target decreased to US$8.25

Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions

Independent Non-Executive Director Bruce Peacock has left the company

Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable

Independent Chairman of the Board recently bought US$354k worth of stock

New 90-day low: US$4.94

Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?

Windtree Therapeutics, Inc. Announces Executive Changes

Windtree Appoints Dr. Joseph Soffer to Lead Cardiovascular Clinical Development

Windtree Therapeutics, Inc.(NasdaqCM:WINT) dropped from S&P TMI Index

Windtree Therapeutics, Inc. Announces First Patient Dosed in its Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19

New 90-day low: US$4.98

Windtree Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients

Windtree Therapeutics, Inc. Announces FDA Acceptance of IND Application for a Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19

New 90-day low: US$5.94

Earnings released

New 90-day high - US$9.90

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies